52916 Federal Register / Vol. 86, No. 182 / Thursday, September 23, 2021 / Notices 

Date: October 24–26, 2021. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: Porter Neuroscience Research 

Center, Building 35A, 35 Convent Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Nina F. Schor, MD, Ph.D., 

Deputy Director, National Institute of 

Neurological Disorders and Stroke, NIH, 

Building 31, Room 8A52, Bethesda, MD 

20892, 301–496–9746, nina.schor@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: September 17, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–20580 Filed 9–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Heart, Lung, 

and Blood Advisory Council. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: October 26, 2021. 

Closed: 10:00 a.m. to 11:00 a.m. 

Agenda: To Review and Evaluate Grant 

Applications. 

Place: National Institutes of Health, 

Rockledge 1, 6705 Rockledge Dr., Bethesda, 

MD 20892 (Virtual Meeting). 

Open: 11:30 a.m. to 5:00 p.m. 

Agenda: To Discuss Program Policies and 

Issues. 

Place: National Institutes of Health, 

Rockledge 1,6705 Rockledge Dr., Bethesda, 

MD 20892 (Virtual Meeting). 

Virtual Access: The meeting will be 

videocast and can be accessed from the NIH 

Videocast. https://www.nhlbi.nih.gov/about/ 

advisory-and-peer-review-committees/ 

advisory-council. Please note, the link to the 

videocast meeting will be posted within a 

week of the meeting date. 

Contact Person: Laura K. Moen, Ph.D., 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6705 

Rockledge Drive, Room 206–Q, Bethesda, MD 

20892, 301–827–5517, moenl@mail.nih.gov 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/nhlbac/ 

index.htm, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 17, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–20584 Filed 9–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; SEP Limited Competition: 

Clinical and Translational Science Award 

(CTSA) Consortium-Wide Centers: Resources 

for Rapid Demonstration and Dissemination 

(U24 Clinical Trials Not Allowed). 

Date: October 20, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1037, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Victor Henriquez, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1037, Bethesda, MD 20817, (301) 435–0813, 

henriquv@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: September 17, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–20582 Filed 9–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Exploratory Studies to Investigate 

Mechanisms of HIV Infection, Replication, 

Latency, and/or Pathogenesis in the Context 

of Substance Use Disorders (R61/R33— 

Clinical Trial Not Allowed). 

Date: October 26, 2021. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 182 / Thursday, September 23, 2021 / Notices 52917 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5843, trinh.tran@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Animal Genomics Program (U01—Clinical 

Trial Not Allowed). 

Date: November 5, 2021. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ipolia R. Ramadan, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–4471, ramadanir@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Assessing the Effects of Cannabinoids on 

HIV-Associated Persistent Inflammation (R01 

Clinical Trial Optional). 

Date: November 19, 2021. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Soyoun Cho, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 594–9460, 

Soyoun.cho@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: September 17, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–20581 Filed 9–22–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–0361. 

Proposed Project: Division of State 

Programs—Management Reporting 

Tool (DSP–MRT) 

(OMB No. 0930–0354)—Revision 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA) Center for Substance Abuse 

Prevention (CSAP) aims to monitor 

several substance use prevention 

programs through the DSP–MRT, which 

reports data using the Strategic 

Prevention Framework (SPF). Programs 

monitored through the DSP–MRT 

include: SPF-Partnerships for Success 

(PFS), SPF- Prescription Drugs (Rx), 

Prescription Drug Overdose (PDO), and 

First Responder-Comprehensive 

Addiction and Recovery Act (FR– 

CARA). SAMHSA also proposed adding 

a new program: Sober Truth on 

Preventing Underage Drinking Act 

Grants (STOP Act). This request for data 

collection includes minor revisions 

from a previously approved OMB 

instrument. 

Monitoring data using the SPF model 

will allow SAMHSA’s project officers to 

systematically collect data to monitor 

their grant program. In addition to 

assessing activities related to the SPF 

steps, the performance monitoring 

instruments covered in this statement 

collect data to assess the following 

grantee required specific performance 

measures: 

• Number of training and technical 

assistance activities per funded 

community provided by the grantee to 

support communities 

• Reach of training and technical 

assistance activities (numbers served) 

provided by the grantee 

• Percentage of subrecipient 

communities that submit data to the 

grantee data system 

• Number of subrecipient communities 

that improved on one or more targeted 

National Outcome Measures 

• Number of grantees who integrate 

Prescription Drug Monitoring Program 

data into their program needs 

assessment 

• Number of naloxone toolkits 

distributed 

Revisions to this package include the 

following: 

• Inclusion of six performance targets 

• Removal of outdated references 

• Adjustments to the language in the 

Disparities Impact Section to refine 

response 

ANNUALIZED DATA COLLECTION BURDEN

Instrument Number of 

respondents 

Responses per 

respondent 

Total number 

of responses 

Hours per 

response 

Total 

burden 

hours 

Average 

hourly 

wage 

Total 

respondent 

cost a

DSP–MRT ..................................................... 521 4 2,084 3 6,252 $44.19 $276,276 

PFS Supplemental ........................................ 253 1 253 1 253 44.19 11,180 

PDO/FR CARA Supplemental ...................... 109 2 218 1 218 44.19 9,633 

SPF Rx Supplemental ................................... 26 4 104 1 104 44.19 4,596 

STOP Act Supplemental ............................... 133 1 133 1 133 44.19 5,877 

FY2021–FY2024 Total ........................... 521 ........................ ........................ ........................ 6,960 ........................ 307,562 

Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the 

search function. 

Carlos Graham, 

Social Science Analyst. 

[FR Doc. 2021–20608 Filed 9–22–21; 8:45 am] 

BILLING CODE 4162–20–P 


lotter on DSK11XQN23PROD with NOTICES1